Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.57 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1130406 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13300471 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL1106644 | 0.91 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13300466 | 0.91 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13300473 | 0.90 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL1106651 | 0.90 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL14260883 | 0.90 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13300470 | 0.90 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL10098847 | 0.90 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13320175 | 0.89 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DRAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153609-B2 | Purine nucleotide derivatives | LAURAS AS (NO) | 2012-04-10 | — | — | US | disclosed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | PDE4A 9/4885PDE4B 11/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.